

#20

RECEIVED
TECH CENTER 1600/2900PATENT

99 AUG 31 AM 10:32

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEApplicant: **Harris et al.**Group Art Unit No.: **1651**Serial No.: **08/259,413**Examiner: **H. Lilling**Filed: **June 14, 1994**For: **PEGYLATION REAGENTS AND
COMPOUNDS FORMED THEREWITH**Docket No.: **S-210C****INFORMATION DISCLOSURE STATEMENT**
UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Copies of the listed documents are enclosed.

This Information Disclosure Statement is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Action (after the Rule 1.129(a) Request was filed on August 16, 1999) or a Notice of Allowance. Please charge Deposit Account No. 01-0519, in the name of Amgen Inc., in the amount of \$240.00, which is the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c). **An original and one copy of this paper are enclosed.**

German Publication No. DE 3910323 A1 is not in English. That document claims the same priority application as Great Britain Publication No. 2218101, which is cited and enclosed. European Publication No. 0417563 A2 is not in English. That document claims the same priority applications as United States Patent No. 5,610,279, a copy of which is enclosed. PCT Publication No. WO 90/13575 is not in English. That document claims the same priority application as United States Patent No. 5,344,915, a copy of which is enclosed. Applicants enclose an English translation of EP 393438.

Applicants also bring to the attention of the Examiner the following copending United States Patent Applications:

08/116,260	filed	9/2/93
08/375,242	filed	1/19/95
08/383,676	filed	2/1/95
08/477,638	filed	6/7/95
08/477,639	filed	6/7/95
08/482,284	filed	6/7/95
08/484,307	filed	6/7/95
08/484,312	filed	6/7/95
08/484,337	filed	6/7/95 (abandoned and petition to revive has been filed)
08/484,783	filed	6/7/95
08/848,292	filed	4/29/97


Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Ron K. Levy

Registration No.: 31,539

for

Thomas D. Zindrick

Attorney/Agent for Applicant

Registration No.: 32,185

Phone: (805) 447-8101

Date: August 30, 1999

Please send correspondence pertaining to this application to:

U.S. Patent Operations/TDZ
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799